Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16673
Title: Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Austin Authors: Parakh, Sagun ;Park, John J;Mendis, Shehara;Rai, Rajat;Xu, Wen;Lo, Serigne;Drummond, Martin;Rowe, Catherine;Wong, Annie;McArthur, Grant;Haydon, Andrew;Andrews, Miles C;Cebon, Jonathan S ;Guminski, Alex;Kefford, Richard F;Long, Georgina V;Menzies, Alexander M;Klein, Oliver ;Carlino, Matteo S
Affiliation: Medical Oncology Unit, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
La Trobe University School of Cancer Medicine, Bundoora, Victoria, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia
The University of Sydney, Sydney, New South Wales, Australia
Medical Oncology Unit, Alfred Hospital, Melbourne, Victoria, Australia
Melanoma Institute Australia, Sydney, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia
Department of Clinical Medicine, Macquarie University, New South Wales, Australia
Issue Date: Jun-2017
metadata.dc.date: 2017-05-18
Publication information: British Journal of Cancer 2017; 116(12): 1558-1563
Abstract: BACKGROUND: There is limited data on the efficacy of anti-programmed death 1 (PD-1) antibodies in patients (pts) with melanoma brain metastasis (BM), particularly those which are symptomatic. METHOD: We retrospectively assessed pts with melanoma BM treated with PD-1 antibodies, nivolumab and pembrolizumab. Clinicopathologic and treatment parameters were collected and outcomes determined for intracranial (IC) response rate (RR) using a modified RECIST criteria, with up to five IC target lesions used to determine IC response, disease control rate (DCR) and progression-free survival (PFS). RESULTS: A total of 66 pts were identified with a median follow up of 7.0 months (range 0.8-24.5 months). A total of 68% were male and 45% BRAF V600 mutation positive. At PD-1 antibody commencement, 50% had an elevated LDH; 64% had local therapy to BM prior to commencing anti-PD1, of which 5% had surgical resection, 14% stereotactic radiosurgery (SRS), 18% whole-brain radiotherapy (WBRT), 27% had surgery and radiotherapy. Twenty-one per cent started anti-PD-1 as first line systemic therapy. No pt had prior anti-PD-1 treatment. The IC overall RR was 21 and DCR 56%. Responses occurred in 21% of pts with symptomatic BM. The median OS was 9.9 months (95% CI 6.93-17.74). Pts with symptomatic BM had shorter PFS than those without symptoms (2.7 vs 7.4 months, P=0.035) and numerically shorter OS (5.7 vs 13.0 months, P=0.068). Pts requiring corticosteroids also had a numerically shorter PFS (3.2 vs 7.4 months, P=0.081) and OS (4.8 vs 13.1 months, P=0.039). CONCLUSIONS: IC responses to anti-PD-1 antibodies occur in pts with BM, including those with symptomatic BM requiring corticosteroids. Prospective trials evaluating anti-PD-1 therapy in pts with BM are underway.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16673
DOI: 10.1038/bjc.2017.142
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28524161
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.